Novel protective role for MAP kinase phosphatase 2 in inflammatory arthritis by Schroeder, Juliane et al.
Schroeder, Juliane and Ross, Kirsty and McIntosh, Kathryn and Jabbar, 
Shilan Khayrula Jabbar and Woods, Stuart and Crowe, Jenny and 
Patterson-Kane, Janet C and Alexander, James and Lawrence, Catherine 
and Plevin, Robin (2019) Novel protective role for MAP kinase 
phosphatase 2 in inflammatory arthritis. RMD Open, 5 (1). e000711. ISSN 
2056-5933 , http://dx.doi.org/10.1136/rmdopen-2018-000711
This version is available at https://strathprints.strath.ac.uk/66560/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
  1Schroeder J, et al. RMD Open 2019;5:e000711. doi:10.1136/rmdopen-2018-000711
Original article
Novel protective role for MAP kinase 
SKRVSKDWDVHLQLQÁDPPDWRU\DUWKULWLV
Juliane Schroeder,1 Kirsty Ross,2 Kathryn McIntosh,3 Shilan Jabber,3 
Stuart Woods,3 Jenny Crowe,1 Janet Patterson Kane,4 James Alexander,3 
Catherine Lawrence,3 Robin Plevin3
To cite: Schroeder J, ross K, 
Mcintosh K, et al. novel 
protective role for MaP kinase 
phosphatase 2 in inlammatory 
arthritis. RMD Open 
2019;5:e000711. doi:10.1136/
rmdopen-2018-000711
 Ź Prepublication history and 
additional material for this 
paper are available online. to 
view these iles, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ rmdopen- 2018- 
000711).
received 23 april 2018
revised 21 november 2018
accepted 25 november 2018
1 institute of infection, immunity 
and inlammation, University of 
glasgow, glasgow, Scotland
2Pure and applied chemistry, 
technology innovation centre, 
University of Strathclyde, 
glasgow, Scotland
3 Strathclyde institute for 
Pharmacy and Biomedical 
Sciences, University of 
Strathclyde, glasgow, Scotland
4Flagship Biosciences inc, 
Massey University, Denver, 
colorado, USa
Correspondence to
Dr robin Plevin;  
 r. plevin@ strath. ac. uk
Animal models
© author(s) (or their 
employer(s)) 2019. re-use 
permitted under cc BY. 
Published by BMJ.
Key messages
What is already known about this subject?
 Ź Previously, we have demonstrated a role for mito-
gen-activated protein kinase phosphatase 2 (MKP-
2) in regulating macrophage function in parasitic 
infections.
What does this study add?
 Ź Here, we demonstrate a novel role for MKP-2 in reg-
ulating inlammatory arthritis through the regulation 
of neutrophil function.
 Ź this study therefore further highlights a prominent 
role for MKP-2 in regulating immune cell function 
and pathological outcomes.
How might this impact on clinical practice?
 Ź Patients presenting with arthritis could be screened 
for MKP-2 expression.
 Ź gene therapy could be used as a tool to rectify de-
creased or absent MKP-2 expression in patients.
ABSTRACT
Objectives We have previously shown mitogen-activated 
protein kinase phosphatase 2 (MKP-2) to be a key 
regulator of proinlammatory cytokines in macrophages. 
in the study presented here, we investigated the role of 
MKP-2 in inlammatory arthritis with a particular focus on 
neutrophils.
Methods to achieve this, we subjected MKP-2 deicient 
and wild type mice to collagen antibody induced arthritis, 
an innate model of arthritis, and determined disease 
pathology. to further our investigation, we depleted 
neutrophils in a prophylactic and therapeutic fashion. last, 
we used chemotaxis assays to analyse the impact of MKP-
2 deletion on neutrophil migration.
Results MKP-2-/- mice showed a signiicant increase in 
disease pathology linked to elevated levels of proarthritic 
cytokines and chemokines tnF-α, il-6 and McP-1 in 
comparison to wild type controls. this phenotype is 
prevented or abolished after administration of neutrophil 
depleting antibody prior or after onset of disease, 
respectively. While McP-1 levels were not affected, 
neutrophil depletion diminished tnF-α and reduced 
il-6, thus linking these cytokines to neutrophils. in vivo 
imaging showed that MKP-2-/- mice had an increased 
inlux of neutrophils into affected joints, which was higher 
and potentially prolonged than in wild type animals. 
Furthermore, using chemotaxis assays we revealed that 
MKP-2 deicient neutrophils migrate faster towards a 
leukotriene B4 gradient. this process correlated with a 
reduced phosphorylation of erK in MKP-2-/- neutrophils.
Conclusions this is the irst study to show a protective 
role for MKP-2 in inlammatory arthritis.
InTROduCTIOn
Rheumatoid arthritis (RA) is a disabling condi-
tion affecting approximately 0.5%–1% of the 
population in Europe and North America,1 
characterised by persistent pain and stiffness 
of the joints, progressive joint destruction, 
functional disability and premature mortality. 
As a multifactorial disease, RA involves both 
the innate and the adaptive arms of the 
immune system. Numerous cellular and clin-
ical studies have implicated the involvement 
of multiple cell types including T cells, B cells, 
macrophages, neutrophils depending on the 
immune context; yet, despite intensive study, 
there are still key deficits in understanding 
the principal mechanisms on how inflamma-
tory arthritis develops.
A major signalling pathway implicated in 
the pathogenesis of RA is the MAP kinase 
pathway involving MAP kinases ERK, p38 
and JNK.2 3 In RA, all three kinases are acti-
vated and implicated to different extents in 
joint inflammation, pannus formation and 
joint destruction. Of these three kinases, ERK 
has recently gained more interest, with one 
study demonstrating the importance of ERK 
in synovial cell death, where it was shown to 
regulate TNF-α-induced expression of B-cell 
activating factor through an increase in 
hypoxia-inducible factor-1α.4 Another study 
highlighted a role for ERK in TNF-α-induced 
IL-8 expression in synovial fibroblasts, which 
contributes to synovitis.5
The kinetics and magnitude of MAP kinase 
activities is closely regulated by a family of 
dual specific phosphatases (DUSPs) known as 
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the MAP kinase phosphatases.6 Three major classes exist, 
each with overlapping subcellular expression, kinase 
specificity and regulation by cellular stimulation.7 In 
contrast to studies involving the MAP kinases, there are 
very little data investigating the role of DUSPs in regu-
lating RA. However, it has been shown that the deletion of 
mitogen-activated protein kinase phosphatase 1 (MKP-1) 
leads to enhanced severity of collagen induced arthritis 
(CIA) and increased cytokine release,8 while DUSP2 
(PAC1) deficient mice showed a reduced response in the 
KxB/N model of inflammatory arthritis.9
MKP-2 (DUSP4) is a type 1 nuclear phosphatase10 
specific for ERK and JNK in vitro. As a type 1 DUSP, 
MKP-2 has been viewed as a surrogate to the prototypic 
MKP-1 and less extensively examined.11 However, more 
recent studies have identified distinct roles for MKP-2 in 
different cellular processes and associated pathologies 
such as tumour development,12 13 cancer resistance,14 
cardiac myopathy,15 infection16 and inflammation. Recent 
studies using KO models have shown that MKP-2 protects 
against septic shock17 and plays a role in regulating T cell 
function.18 Moreover, MKP-2 deletion mice developed in 
our laboratory have been shown to be highly susceptible 
to parasite infection with Leishmania mexicana and Toxo-
plasma gondii due to alterations in macrophage iNOS/
arginase expression.19 20 Bone marrow-derived macro-
phages that have been stimulated with lipopolysaccha-
ride (LPS) showed an increase in proinflammatory IL-6, 
IL-12, TNFα and a decrease in anti-inflammatory IL-10 
in the absence of MKP-219. This cellular and functional 
phenotype marks MKP-2 as distinct from other MKPs and 
therefore this DUSP has the potential to play a unique 
role in the pathogenesis of other diseases.
In this study, we examined the potential role of MKP-2 
in the pathogenesis of RA using MKP-2 deficient mice 
and the collagen antibody-induced arthritis (CAIA) 
model with a specific focus on neutrophil function and 
migration.
MaTeRIals and MeTHOds
Mice
Male MKP-2 wild-type and deficient mice were bred onto 
a C57BL/6 background as previously described19 and 
maintained under specific pathogen-free conditions 
in the animal facilities at the University of Strathclyde. 
Animals were used at 6–9 weeks of age and were age 
matched within each experiment. All experiments were 
conducted under Project Licenses, RP (PPL60/3439), 
JA (PPL60/3929) and CEL (PPL60/4297) granted 
by the UK Home Office and approval from the local 
ethical committee.
Collagen antibody-induced arthritis and neutrophil depletion
Mice received a single dose (2 mg) of ArthritoMab (MD 
Bioscience) i.p. on day 0, followed by a single dose (100 
µg i.p.) of E. coli O55:b5 LPS (MD Bioscience) i.p. on 
day 3 (n=5). Negative control mice received either 
phosphate buffered saline (PBS) on day 0 and LPS 
on day 3 (n=3) or PBS on both days (n=2) again i.p. 
Body weight, paw measurements and disease score were 
monitored daily. For paw measurements, both front 
and rear paw thickness were determined with a calliper 
and the measurements from day 0 were deducted to 
obtain the inflammation induced increase in paw size.
The arthritic disease score was determined as previ-
ously described:21 0: no reaction, normal; 1: mild but 
definite redness and swelling of the ankle or apparent 
redness and swelling limited to individual digits, regard-
less of the number of digits; 2: moderate redness and 
swelling of the ankle; 3: severe redness and swelling of 
the entire paw including digits; 4: maximally inflamed 
limb with involvement of multiple joints. The score 
was averaged for the front paws and rear paws for each 
mouse.
Neutrophils were depleted in vivo with a single dose 
of 0.25 mg NIMP-R14 (AdipoGen) i.p. as previously 
described22 and depletion monitored using flow cytom-
etry. To control for NIMP-R14 neutrophil depletion, we 
used an isotype control: LEAFTM Purified Rat IgG2b,κ 
Isotype control Antibody (BioLegend, UK).
Histology
After termination of the experiment, the front and rear 
paw and knee of each mouse were removed, skinned 
and fixed in 10% formalin (Sigma-Aldrich). Samples 
were decalcified in 5.5% EDTA for 30 days, washed and 
stored in 70% ethanol at 4°C. For processing, samples 
were paraffin-embedded under vacuum and sections 
stained with H&E at the University of Glasgow Veteri-
nary School, before being scored blindly by a patholo-
gist as previously described.23
Flow cytometry
Seventy microlitres of blood were taken with heparin-
ised glass capillaries from the tail. After blocking unspe-
cific binding with 10% mouse serum and Fc receptor 
blocking antibodies (anti-mouse CD16/32, eBiosci-
ence, UK), the cell surface was stained with conjugated 
antibodies for CD11b (Pe-Cy7; eBioscience, UK), and 
Ly-6G (IA8 clone, APC-Cy7; BioLegend) for 45 min at 
4°C. Red blood cells were lysed using FACS Lyse (BD 
Bioscience) for 10 min after which cells were washed 
and resuspended in 200 µl PBS. Cells were analysed on 
the FACS Canto flow cytometer (BD Bioscience) using 
FACS Diva software.
elIsa
Mouse serum and joint homogenates were analysed 
individually for the presence of IL-6, TNF-α, IL-1β and 
MCP-1 using the ELISA MAX Deluxe Set (BioLegend) 
following manufacturer’s instructions. Absorbance 
was read at 450 nm using a plate reader (Spectramax 
190, Molecular Devices, USA) and concentrations were 
determined against standard curves.
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In vivo imaging (IVIs)
Mice received 200 mg/kg luminol i.p. and were anaes-
thetised for imaging after 10 min.24 Images were taken 
using the IVIS Spectrum (Caliper Life Sciences) with 
medium binning and 5 min exposure time after which 
mice were allowed to recover. Images were analysed 
using the Living Image software (Caliper Life Sciences). 
Briefly, regions of analysis of the same size were drawn 
using the photographs and adjusted as required using 
the overlay. Values were averaged from the two front and 
rear paws, respectively, and for each individual mouse 
and the background deducted. Values are expressed as 
photons per second (p/s).
Chemotaxis assays
Bone marrow neutrophils from MKP-2+/+ and MKP-2-/- 
mice were isolated on LS magnetic columns using the 
Ly-6G positive selection kit (Miltenyi Biotec GmbH, 
Germany) following manufacturer’s instructions. 
Chemotaxis was assessed using 24-well transwell plates 
containing polycarbonate filter membranes of 10 µm 
thickness and 3 µm pore size (Corning). Neutrophils 
were resuspended in complete Roswell Park Memo-
rial Institute (RPMI) media at 2×105/100 µl and were 
added to the upper chamber. The lower chamber was 
filled with 600 µl complete RPMI supplemented with 
either nothing (negative control), LPS (0.5 µg/mL), 
C5a (20 nM) or LTB
4
 (300 nM). Each variable was 
carried out in triplicate. Following 3 hour incubation at 
37°C, the contents of the lower chamber were collected 
and counted. Results were expressed as percentage 
migration ((number of migrated cells/total number of 
cells) ×100).
Western blotting
Neutrophils were isolated as described above and re-sus-
pended in complete RPMI, 1×106 cells were used per 
treatment point. Following stimulation samples were 
analysed by Western blotting as outlined previously.19
statistics
Statistical analysis was performed using GraphPad 
Prism (V.4.0, San Diego, California, USA). All error 
bars are shown as SE of the mean (SEM), with two-tailed 
unpaired t-test, with the exception of Western blots, 
which were one-way ANOVA with Bonferroni’s post-test 
(*p<0.05, **p<0.01, ***p<0.001).
ResulTs
MKP-2 deiciency results in increased inlammation and 
disease pathology
MKP-2 deficient mice showed a significant increased 
disease score compared with wild type mice for both 
front and rear paws. In contrast, control mice showed 
no signs of pathology (figure 1A). Consistent with an 
increased disease score, these mice showed a signif-
icant increase in paw size (online supplementary 
figure S1). Analysis of the serum at day 9 showed a 
dramatic increase of cytokines IL-6 and TNF-α as well as 
chemokine MCP-1 in MKP-2-/- mice compared with wild 
type and control mice (figure 1B). We further deter-
mined the presence of these cytokines in joint homoge-
nates. However, while slightly increased in MKP-2-/-, 
these results are not statistically significant (online 
supplementary figure S2).
Histology on H&E stained sections of front paws, rear 
paws and knees showed a significant joint pathology 
in MKP-2-/- mice with increased infiltration and hyper-
plasia (figure 1C). Taken together, these results indi-
cate that MKP-2 deficiency results in significant disease 
pathology in collagen antibody-induced arthritis.
Inlammation is linked to increased neutrophil migration into 
the joints and can be inluenced by neutrophil depletion
Neutrophils have been previously linked to arthritic 
disease.25 In order to visualise myeloperoxidase-con-
taining neutrophil influx into the joints, mice were 
injected with luminol. In vivo imaging revealed that 
MKP-2 deficient mice showed a significant increase in 
neutrophils in the joints compared with wild type and 
control mice (figure 2).
We next investigated how depletion of neutrophils 
affects disease development. Mice were divided into 
four groups; an overview of the respective treatments is 
shown in figure 3A. Mice in the positive control group 
(+ve control) received ArthritoMab at day 0, followed 
by LPS at day 3 and in addition received an isotype 
control instead of the neutrophil depletion antibody. 
These mice developed pathology with MKP-2-/- showing 
higher disease scores similar to previous observations. 
Mice of the negative control group (–ve control) were 
injected with PBS on both days but in addition received 
neutrophil depleting antibody NIMP-R14 6 hour prior 
to the second PBS injection to ensure that neutrophil 
depletion on its own does not influence disease.
The successful depletion of neutrophils was moni-
tored by flow cytometry and by in vivo imaging 
(figure 3B) and as expected, these mice did not show 
any significant pathology. Mice of the prophylactic 
group were treated with NIMP-R14 6 hours prior 
to LPS injection and before the onset of disease. No 
disease pathology in respect to arthritis was found in 
these mice. Similar effects have been found in the ther-
apeutic group, where neutrophil depletion at day 6, 
after onset of disease, resulted in rapid amelioration of 
disease symptoms (figure 3C).
Concentrations of the cytokines TNF-α and IL-6 
were below detection (TNF-α) or down to levels of the 
negative controls (figure 3D and online supplementary 
figure 4). Interestingly, concentrations of MCP-1 were 
unaffected by neutrophil depletion, thus suggesting 
that neutrophils are not the source of this chemokine.
At this point, most animals in the prophylactic 
group treated with the NIMP-R14 antibody prior to 
LPS became severely ill and showed signs of endotoxic 
shock. Although mice in this group made a full recovery, 
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Figure 1 MKP-2 deiciency results in increased inlammation and arthritis related pathology. Mice received a single dose 
of ArthritoMab at day 0 and a single injection of LPS at day 3. Negative control groups received either PBS on both days or 
PBS on day 0 followed by a single dose of LPS at day 3. Disease development was observed over a period of 9 days. (A) 
Arthritic score was determined as described in materials and methods, MKP-2+/+ (solid line and symbols), MKP-2-/- (dashed 
line and open symbols). (B) Serum cytokines were determined by ELISA, controls are a combination of all negative control 
groups. (C) H&E stained tissue sections (left panels) of front paw, rear paw and knee joints were scored blindly and evaluated 
for iniltration and hyperplasia (right panels). Arrows point to the respective pathology shown on a representative example of 
an MKP-2-/- knee joint. Scores of all three joints were averaged per mouse and plotted as MKP-2+/+ (solid bars) and MKP-2-
/- (open bars). For the total score, scores for joint iniltration and hyperplasia were summed for each individual mouse. All error 
bars are shown as SE of the mean (SEM). *P≤0.05, **P≤0.01, ***P≤0.001, ****P<0.0001, two-tailed unpaired T test. Data shown 
are representative of three independent experiments (mouse numbers; pilot—PBS ctrl=2, LPS ctrl=2, ArthritoMab/LPS=6; Exp 
2—PBS ctrl=4, LPS ctrl=6, ArthritoMab/LPS=10; Exp 3—PBS ctrl=4, LPS ctrl=6, ArthritoMab/LPS=10 *(Totals across MKP+/+ 
and MKP-/- genotypes, with equal numbers in each).
the serum across the groups showed a high variation of 
IL-6, MCP-1 and TNF-α (online supplementary figure 
S4); therefore, no conclusion can be drawn as these are 
more likely to be the result of a cytokine storm than 
arthritis. For this reason also, this experiment was only 
conducted twice, and for the second experiment, the 
prophylactic group was omitted due to the previous 
endotoxic shock observed.
Histological analysis of affected joints showed that 
treatment with neutrophil depleting antibody abolished 
arthritis related pathology in MKP-2-/- mice (online 
supplementary figure S3) to the level of naive mice. 
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Figure 2 MKP-2-/- mice show an increased neutrophil iniltration into the joints. Mice received a single dose of ArthritoMab 
(AB) at day 0 and a single injection of LPS at day 3. Negative control groups received either PBS on both days or PBS on day 
0 followed by a single dose of LPS at day 3. Disease development was observed over a period of 9 days. Neutrophils were 
visualised 10 min after i.p. injection of luminol and resulting bioluminescence was detected using in vivo imaging. Shown is 
a representative image from day 7 (left panels) and the quantiication over the duration of the experiment for front and rear 
paws (right). Red arrows indicate neutrophil inlux. Values are expressed as photons per second (P/S). All error bars are shown 
as SE of the mean (SEM). *P≤0.05, **P≤0.01, two-tailed unpaired T test. Data shown are representative of three independent 
experiments (mouse numbers; pilot—PBS ctrl=2, LPS ctrl=2, ArthritoMab/LPS=6; Exp 2—PBS ctrl=4, LPS ctrl=6, ArthritoMab/
LPS=10; Exp 3—PBS ctrl=4, LPS ctrl=6, ArthritoMab/LPS=10 *(Totals across MKP+/+ and MKP-/- genotypes, with equal 
numbers in each).
Overall, these experiments point to neutrophils as the 
main mediator of inflammation since specific deple-
tion of this cell type prevents or ameliorates disease and 
cytokine levels are ablated after neutrophil depletion.
MKP-2 deicient neutrophils show increased chemotaxis
We next performed transwell assays to determine if the 
increased migration is a result of MKP-2 deficiency. As 
chemo-attractants we chose C5a and Leukotriene B4 
(LTB
4
) as these agents are known to have strong chem-
otactic effects on neutrophils. Neutrophils showed an 
increased migration towards both C5a and LTB
4
. The 
migratory effect was significantly enhanced in MKP-2-/- 
neutrophils in response to LTB
4
 (p<0.05), but no signif-
icant difference was seen with C5a (figure 4A).
We then sought to correlate this difference with 
changes in MAP kinase activity. We found that LTB
4
 
strongly phosphorylated ERK in both groups; however, 
there was no significant difference between MKP-2-/- and 
MKP-2+/+ neutrophils (figure 4B). LTB
4
 did not appear 
to activate the p38 pathway and therefore no compari-
sons could be made. In comparison we found that in 
MKP-2+/+ neutrophils, C5a gave a strong activation of 
ERK peaking at 5 min and this response was markedly 
reduced in MKP-2-/- neutrophils (p<0.001) (figure 4C). 
C5a was also able to phosphorylate p38 MAPK, although 
to a smaller level (n.s), and this was not significantly 
altered by DUSP4 deletion (figure 4C). In contrast, no 
JNK phosphorylation was detected in any of the samples 
(not shown).
dIsCussIOn
Using MKP-2 deficient mice developed in our laboratory, 
we present for the first time evidence that MKP-2 plays a 
key protective role in inflammatory arthritis. MKP-2 has 
been implicated in both inflammatory responses and 
infection with particular emphasis on macrophages and 
T-cell function. In this study, we show that in an innate 
model of arthritis neutrophils are also influenced by 
MKP-2, and MKP-2 deficient neutrophils migrate to the 
joint more rapidly to mediate join destruction through 
enhanced cytokine release.
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Figure 3 Neutrophil depletion prevents and ameliorates inlammation. Mice were divided into four groups of ive animals per 
genotype and received treatment as shown in (A). All groups but the negative controls received ArthritoMab at day 0 and LPS 
at day 3. Neutrophils at day 3 were depleted 6 hour prior to i.p. injection of LPS or PBS in the prophylactic and negative control 
groups, respectively. The therapeutic groups received NIMP after onset of disease at day 6. (B) Neutrophil depletion from blood 
before and after treatment with NIMP from MKP-2-/- mice from the therapeutic group was monitored using low cytometry 
with speciic staining for CD11b and Ly-6G (left panels) and also via bioluminescence (right panels) following luminol injection. 
(C) Disease scores were determined as described in materials and methods, closed symbols depict MKP-2+/+ mice and open 
symbol depicts MKP-/- mice. (D) Serum cytokines were determined using ELISA. All error bars are shown as SE of the mean 
(SEM). Data shown are representative of two independent experiments. (Mouse numbers; Exp 1: ArthritoMab/LPS=10, PBS/
NIMP=10, Prophylactic=10 and Therapeutic=10; Exp 2: ArthritoMab/LPS=6, PBS/NIMP=0, Prophylactic=0 and Therapeutic=6; 
*(Totals across MKP+/+ and MKP-/- genotypes, with equal numbers in each).
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Figure 4 MKP-2 deicient neutrophils show increased chemotactic activity in vitro. (A) Puriied neutrophils were subjected 
to Transwell migration assays using LPS (0.5 µg/mL), C5a (20 nM) and LTB
4
 (300 nM) as chemoattractants. Migrating cells are 
shown as percentage of the overall population. (B) Neutrophils were stimulated with LTB
4
 (300 nM) over a time course and cell 
extracts were analysed for the presence of phosphorylated ERK and p38. (C) Neutrophils were stimulated with C5a (20 nM) 
over a time course and cells’ extracts analysed for the presence of phosphorylated ERK and p38. Membranes were stripped 
and reprobed for their respective totals. All error bars are shown as SE of the mean (SEM), *p≤0.05, **p≤0.01, ***p≤0.001. (A) 
Two-tailed unpaired t test, (B,C) One-way ANOVA with Bonferroni’s post-test. (C,D) Closed symbols depict MKP-2+/+ mice and 
open symbol depict MKP-/- mice. Data shown are representative of three independent experiments (mouse numbers—four 
mice from each genotype, so a total of eight were used per each independent experiment).
In this study, enhanced damage to the joint in MKP-2-
/- mice was accompanied by a marked increase in serum 
levels of MCP-1, IL-6 and TNFα. This is in line with 
observations made in MKP-1-/- mice which received LPS 
injections8 and suggests common regulatory functions 
between nuclear inducible DUSPs. However, these results 
are different from another DUSP-4 deletion model which 
showed reduced serum levels of TNFα in response to 
LPS.17 Differences in the dose of LPS and the time at 
which TNFα was measured is likely to explain the differ-
ences; however, in our hands, MKP-2-/- macrophages 
also show enhanced TNFα production,19 suggesting an 
intrinsic difference in cytokine production in DUSP-4 
deficient cells of myeloid origin compared with WT.
Nevertheless, to our surprise, depletion of neutrophils 
completely abrogated serum TNFα, which indicates that 
neutrophils are the main producer of this cytokine in 
the CAIA model. This is consistent with other studies 
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indicating the potential of neutrophils to be a source 
of TNFα and other related ligands following innate 
immune challenge.26 Interestingly, MCP-1, which is 
associated with inflammatory arthritis, was not affected 
suggesting a different source. While many cells are able 
to produce MCP-1, it has been shown that monocyte/
macrophages are the main producer.27 When examining 
joint pathology, we found that neutrophil depleted mice 
showed a significantly reduced pathology score. This 
raises the question as to what extent each cytokine/
chemokine contributes to joint destruction. It is known 
that proinflammatory cytokines, TNFα, IL-6 and IL-1 
can indirectly trigger osteoclastogenesis by upregulating 
RANKL on the surface of osteoblasts.28 On the other 
hand, MCP-1 induces RANKL expression on osteoclast 
precursor cells, a process which is ERK dependent.29 It 
is therefore possible that the lack of TNFα caused after 
neutrophil depletion results in a decrease of RANKL on 
osteoblasts, crucial for osteoclast activation, which would 
explain why the presence of MCP-1 alone did not result 
in joint damage. This would be something that could be 
investigated in future studies.
Since neutrophils appear to be the key cell type respon-
sible for the pathology observed, we addressed the ques-
tion whether MKP-2 deficiency alters chemotactic activity. 
Isolated neutrophils displayed migration towards both 
C5a and LTB
4
; however, MKP-2-/- neutrophils showed a 
significantly increased migration towards LTB
4
, a potent 
chemoattractant to neutrophils, and indeed Finsterbusch 
and coworkers have shown that neutrophils recruited by 
these chemoattractants release TNFα leading to micro-
vascular leakage and inflammation.30 Recent studies have 
revealed that LTB
4
 is a key mediator in a complement, 
lipid, cytokine and chemokine cascade that first initiates 
and then sustains neutrophilic inflammation in inflam-
matory arthritis31
Stimulating neutrophils with either LTB
4
 or C5a resulted 
in a strong phosphorylation of ERK which was reduced 
following MKP-2 deletion. Work by Liu et al showed that 
ERK is a negative regulator of migration32 and this would 
be consistent with our finding that in MKP-2-/- neutrophils 
ERK is reduced, negative regulation is abrogated and 
migration enhanced. In contrast, p38 MAPK, believed to 
provide a positive chemotaxis signal, was not significantly 
altered in our studies. However, it should be noted that 
our expectation from a signalling perspective is that ERK 
activation may have been enhanced due to lack of regu-
latory dephosphorylation by MKP-2. This suggests MKP-2 
deletion may have effects which regulate other compo-
nents of the ERK cascade including receptor expression 
and functional coupling to upstream intermediates. A 
number of studies including our own have also suggested 
that MKP-2 can regulate cellular function in a way which 
is not dependent on the normal predicted effects on ERK 
and JNK.11 33 34 Indeed, recently MKP-2 has been shown 
to interact and regulate the cell cycle protein VRK-1 inde-
pendently of phosphatase activity suggesting multiple 
cellular effects.35 Another coincidental explanation may 
be pathway redundancy and/or cross talk with MKP-1, 
such that ERK signalling is altered in a different way.17
Finally, another possibility, not examined in this study, 
is that MKP-2 may regulate apoptosis and indeed MKP-2 
deficient neutrophils are present in far greater numbers 
and appear to reside in the joint for longer, possibly 
prolonging the release of cytokines. This would be consis-
tent with studies that show delayed neutrophil apoptosis 
in response to LTB
4
36 and L. major infection.37 Indeed, 
MKP-2 deletion results in the inhibition of B- cell apop-
tosis38 and also enhances T cell proliferation18 consistent 
with this idea.
Overall, our novel findings suggest that MKP-2 has the 
potential to play a major role in regulating RA due to a 
direct effect on neutrophil function, with the potential to 
effect macrophages, osteoclast formation and bone devel-
opment. The use of specific conditional knockout mice 
would allow further dissection of these events. However, 
it remains that MKP-2 may be an attractive target for gene 
replacement therapy.
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